Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra W Cowan-Jacob

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry|September 7, 2010
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinibPaul W Manley, Nikolaus Stiefl, Sandra W Cowan-Jacob, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2010
New pyrazolo[1,5a]pyrimidines as orally active inhibitors of LckNina Gommermann, Peter Buehlmayer, Anette von Matt, et al.
Mini Reviews in Medicinal Chemistry|March 23, 2004
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatmentSandra W Cowan-Jacob, Valerie Guez, Gabriele Fendrich, et al.
ACS Chemical Biology|July 10, 2015
Type II Inhibitors Targeting CDK2Leila T Alexander, Henrik Möbitz, Peter Drueckes, et al.
Acta Crystallographica. Section D, Biological Crystallography|December 14, 2006
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiaSandra W Cowan-Jacob, Gabriele Fendrich, Andreas Floersheimer, et al.
Journal of Medicinal Chemistry|October 15, 2013
Efficient search of chemical space: navigating from fragments to structurally diverse chemotypesAnne Mai Wassermann, Peter S Kutchukian, Eugen Lounkine, et al.
Journal of the American Chemical Society|May 11, 2010
Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assayWolfgang Jahnke, Robert M Grotzfeld, Xavier Pellé, et al.
Journal of Medicinal Chemistry|September 11, 2010
Expanding the diversity of allosteric bcr-abl inhibitorsXianming Deng, Barun Okram, Qiang Ding, et al.
Cancer Research|June 3, 2005
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsThomas O'Hare, Denise K Walters, Eric P Stoffregen, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymesMaurice J van Eis, Jean-Pierre Evenou, Philipp Floersheim, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry|September 7, 2010
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinibPaul W Manley, Nikolaus Stiefl, Sandra W Cowan-Jacob, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2010
New pyrazolo[1,5a]pyrimidines as orally active inhibitors of LckNina Gommermann, Peter Buehlmayer, Anette von Matt, et al.
Mini Reviews in Medicinal Chemistry|March 23, 2004
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatmentSandra W Cowan-Jacob, Valerie Guez, Gabriele Fendrich, et al.
ACS Chemical Biology|July 10, 2015
Type II Inhibitors Targeting CDK2Leila T Alexander, Henrik Möbitz, Peter Drueckes, et al.
Acta Crystallographica. Section D, Biological Crystallography|December 14, 2006
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiaSandra W Cowan-Jacob, Gabriele Fendrich, Andreas Floersheimer, et al.
Journal of Medicinal Chemistry|October 15, 2013
Efficient search of chemical space: navigating from fragments to structurally diverse chemotypesAnne Mai Wassermann, Peter S Kutchukian, Eugen Lounkine, et al.
Journal of the American Chemical Society|May 11, 2010
Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assayWolfgang Jahnke, Robert M Grotzfeld, Xavier Pellé, et al.
Journal of Medicinal Chemistry|September 11, 2010
Expanding the diversity of allosteric bcr-abl inhibitorsXianming Deng, Barun Okram, Qiang Ding, et al.
Cancer Research|June 3, 2005
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsThomas O'Hare, Denise K Walters, Eric P Stoffregen, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymesMaurice J van Eis, Jean-Pierre Evenou, Philipp Floersheim, et al.
Pageof 4